Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing

M. S. Hershfield, J. T. Callaghan, W. Tassaneeyakul, T. Mushiroda, C. F. Thorn, T. E. Klein, M. T.M. Lee

Research output: Contribution to journalReview article

129 Scopus citations

Abstract

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B 58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number2
DOIs
StatePublished - Feb 1 2013

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing'. Together they form a unique fingerprint.

  • Cite this